NSI-189 is an investigational small molecule developed by Neuralstem for research on hippocampal function, depression and cognition. Its commonly studied form is the phosphate salt. The page reviews early clinical trials and proposed effects on neural progenitor cells, while distinguishing this compound from the chemically different racetam family.
What Is NSI-189 (NSI-189 Phosphate)?
NSI-189 is an investigational small-molecule neurogenic compound developed by Neuralstem Inc. The commonly studied pharmaceutical form is NSI-189 phosphate, a salt intended to improve handling and oral formulation. The compound was designed as a potential treatment for disorders involving impaired hippocampal structure or function, including major depressive disorder and cognitive dysfunction. Unlike conventional antidepressants, whose primary pharmacological targets often include serotonin, norepinephrine, or dopamine transporters and receptors, NSI-189 was developed around the idea that stimulating endogenous neural progenitor cells could promote structural and functional recovery in the hippocampus.
NSI-189 is not a racetam. It belongs to the benzylpiperazine aminopyridine chemical family and should not be categorized with piracetam, aniracetam, oxiracetam, pramiracetam, or other racetam derivatives. Its proposed activity is also distinct from the commonly discussed AMPA-receptor-modulating or ampakine-like mechanisms associated with some racetam-related compounds. Early Phase I and Phase II clinical trials evaluated NSI-189 phosphate in adults with major depressive disorder. Those studies reported acceptable short-term tolerability and signals involving depressive symptoms, cognition, and hippocampal-related measures, but the evidence remains preliminary and does not establish NSI-189 as an approved antidepressant, neuroprotective agent, or cognitive enhancer.
Quick Reference
Member reference tables summarize the compound's research parameters.
A randomized phase II study in major depressive disorder evaluated oral NSI-189 phosphate and reported improvement on selected depression rating outcomes versus placebo; findings require replication.
Cognitive symptoms in depression
Exploratory clinical measures suggested possible effects on cognitive domains associated with depression, but the evidence base remains small and investigational.
Neurogenesis and Neuroplasticity
Preliminary Data
Hippocampal progenitor-cell models
NSI-189 was developed following preclinical observations of increased neural progenitor-cell proliferation and neurogenesis-related effects in experimental systems.
Stress-related structural changes
The proposed neuroplasticity mechanism is biologically plausible in mood-disorder research, but direct confirmation of hippocampal neurogenesis in treated humans is unavailable.
Cognition and Traumatic Brain Injury
Emerging Evidence
Cognitive performance
Claims regarding memory, attention, or executive function are not established by adequate clinical trials in healthy individuals.
Brain-injury applications
Preclinical rationale has prompted interest in neurological recovery, but NSI-189 is not an approved treatment for traumatic brain injury or other neurological conditions.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Request a lot-specific COA identifying NSI-189 phosphate, its salt form, lot number, test date, and the laboratory or analytical method used.
Verified Marker
Independent HPLC or LC-MS identity testing
Prefer chromatographic purity testing paired with mass-spectrometric identity confirmation, rather than an unsupported percentage-purity claim.
Verified Marker
Heavy-metal and microbiological screening
For oral capsules or powders, documentation should include heavy-metal limits and appropriate microbial testing for the finished product.
Acceptable Range
Capsule fill-weight accuracy
Capsule labeling should clearly state milligrams of NSI-189 phosphate per capsule and distinguish active mass from excipients; batch-to-batch uniformity data are preferable.
Quality Concern
Research-only labeling without traceable testing
The listed research text specifies avoiding products lacking a verifiable lot number, third-party analytical report, manufacturer contact information, or consistency between the label and COA.